Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Mar 10, 2009


DNAStar has released an update to its gene expression analysis software, ArrayStar. ArrayStar version 3.0 offers more functions for normalization, gene ontology, and data transformations. The software also has an optional module, QSeq, that is designed to accept sequence data from next-generation platforms and use it in digital gene expression and RNA-Seq applications.

SoftGenetics has added a quantification feature to its Mutation Surveyor DNA variant analysis software that provides status quantification of specific nucleotides of Sanger sequencing traces. The new feature is valuable for a variety of applications, according to the company, including disease study and diagnosis, antibiotic resistance in bacteria, and heteroplasmy studies of mitochondrial DNA.

Release 41 of COSMIC, the Catalog of Somatic Mutations in Cancer, is available here. For the new release, 44 genes have been updated with the addition of 22,516 samples and 7,387 mutations.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.